Background: The current study aims to investigate the expression of lncRNA BLACAT1 in patients with acute myeloid leukemia (AML) and to analyze its correlation with clinical prognosis.
Methods: Peripheral blood samples were collected from 68 AML patients, including 48 patients with acute myeloid leukemia (AML), 20 patients with complete response (CR), and 30 patients with iron deficiency anemia (control group). LncRNA BLACAT1 was detected by real-time fluorescence quantitative PCR (qRT-PCR). The expression of BLACAT1 and its relationship with clinicopathological characteristics and prognosis were analyzed. Results: The expression of lncRNA BLACAT1 in AML patients was significantly higher than that in complete remission patients and iron deficiency anemia patients, but the expression of lncRNA BLACAT1 in AML-CR group and control group had no significant difference. Further study showed that the expression of lncRNA BLACAT1 was correlated with the National Comprehensive Cancer Network (NCCN) risk classification, the amount of platelet and bone marrow primordial cells (%), and survival status of patients. The median overall survival time of patients with high expression of lncRNA BLACAT1 was significantly shorter than those with low expression of lncRNA BLACAT1 (p < 0.05).
Conclusions: LncRNA BLACAT1 was involved in regulating the occurrence and development of AML and can be used as a potential prognostic marker and therapeutic target for AML patients.